Lilly Diet Drug - Search News

Eli Lilly, weight loss

Hosted on MSN · 16h

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

Becker's Hospital Review · 1d

New weight loss pill to be approved by early 2026: Eli Lilly

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Lilly asks to join lawsuit over compounded versions of its weight-loss drugs

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.

Lilly shares on track for worst day since 2021

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.

MarketWatch · 1d

Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,

Investopedia on MSN · 1d

S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens

Key Takeaways The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's consumer price report.Eli Lilly shares plunged after the pharma giant cut its sales guidance,

1d

Maker of weight-loss drugs to ask Trump to pause price negotiations: Report

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

13h

Eli Lilly: Big 2025 Ahead, But Execution Risks Exist

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Insider Monkey1d

Why Eli Lilly (LLY) Stock Is Declining Today

Eli Lilly blamed the shortfall on lower-than-anticipated demand for its weight-loss drugs. Indeed, the drug maker ...

1d

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

4d

FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

5don MSN

High cost of weight loss drugs drives employers to require nutrition counseling, in boost for startups

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results